We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon
Investor in the best interests of our community. For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
After 2002, I'm not confident enough to answer that question directly. You probably already have an idea of what I like anyway.
If I were searching for best ideas I would spend some time in the 2003 contest entries; but keep in mind some are not actually owned by the contestants and even if owned are unlikely to be owned in those proportions, or if ever owned, then no longer so.
Looks like there are lots of folks waiting to see if another offer comes in. Only 1/5 of the total float has traded since the J&J offer. Insiders will control the voting since they own 59 of the shares. So the writing may already be on the wall, but I am holding for a while. Just hoping for a better offer. Anyone else?
No, but good luck. I took the cash and walked. Walked ticked. I feel as though I've met "high throughput Corvas", where we can translate faster screening to faster burn.
I think that the Board decided to get a good deal for management and employees, while making a decision to protect shareholders from potential downside.
A critical mistake, in-licensing such a huge amount of burn -- applied so far from market -- in this funding environment. I could only interpret the move in context that management was anticipating good news re. more than one project. And then, for a prolonged period....... nada.
Silly error. It was sort of stunning at the time, sort of "there must be something good, in the deeper works" stunned. After all, there was the milestone payment for thrombin inhibitors, the Athersys (sexy, for me) deal, and all of that time on the discoverworks learning curve, right?
So...... I hope that most jobs are secure. It looks like they are. It may be a good move by the Board. Certainly looks like JNJ got a good look at the company, so they're probably just picking low hanging fruit in this difficult period for biotech.